Market Cap 80.69M
Revenue (ttm) 0.00
Net Income (ttm) -22.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 271,300
Avg Vol 1,068,726
Day's Range N/A - N/A
Shares Out 60.67M
Stochastic %K 25%
Beta 0.30
Analysts Sell
Price Target $14.00

Company Profile

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Industry: Biotechnology
Sector: Healthcare
Phone: 312 416 8592
Address:
444 West Lake Street, Suite 1700, Chicago, United States
focafoca99
focafoca99 Apr. 3 at 8:44 PM
$MAIA paid one-time bonuses to CEO Vlad Vitoc and finance head Jeffrey Himmelreich for work tied to the recent capital raise.
2 · Reply
LabPsycho
LabPsycho Apr. 3 at 8:18 PM
$MAIA @GISBlaster98 Have I not been posting my concerns about these guys well over a year ago? I would love to be able to hype my research, dump a ton of shares and raise 10's of millions of $$$ to at least keep a great salary coming in. How many more signs to people need this is at least a bit curious? In my opinion Cons: *Crypto gimmick * Pumper articles * Pumper video * Outrageous claims by CEO *Big pharma collaborators but not paying $$$ *Dilution, dilution and dilution more than 1 X per year * Licensed tech from somebody else * Lots of foreign collaborators * Claim of second gen Thio is a yawner IMO (i read the paper) Pros: * NIH grant (very difficult to get!) * Big pharma collaborators * Some cash for a while and still not too many shares = easy for Pump-It-Up Round 3 * My spectacular advanced ideas posted here for them for FREE of how to parlay potentially and 5X the value of their asset. * I have other ideas for them too...but why bother...nothing but crickets
2 · Reply
Chemaster
Chemaster Apr. 3 at 4:39 PM
$MAIA I'm so happy I've been here before and remain steady. Last March, I was down heavy on a stock but felt confident in the true value and didn't sell a share. Six months later the stock went up 60% and then I sold half at the top. This same situation has happened multiple times but it is difficult at times. I learned to look at value. This stock is worth $3 to $5 currently with no further data, just having strong Phase 2 data, being in Phase 3 with plenty of cash, having pan-cancer potential, specifically targeting cancer cells and leaving healthy cells untouched. The Interim Data will be here this year and if successful Big Pharma will be throwing cash at MAIA for a partnership considering the 2028 Patent Cliff. Be careful, after this long wait it's easy to sell far too soon and miss the pop. For me, I just walk my dog every morning to chill. Good Luck, steady now.
0 · Reply
Movenu
Movenu Apr. 3 at 1:28 AM
$MAIA Really wishing I sold when it hit $3 back in January but I felt so confident this would be a $10 stock soon. This company delivers as much bad news as it does good. And even the good news isn't moving the needle much lately.
2 · Reply
beforethedeluge
beforethedeluge Apr. 2 at 8:54 PM
$MAIA This thing is a year away and phase 2 doesn't mean crap. There are no guarantees. Price action looks awful. Maybe it's time to cut back a bit.
1 · Reply
GISBlaster98
GISBlaster98 Apr. 2 at 8:19 PM
$MAIA Boo! A bonus buried before a three day weekend! Geeze raise capital and give it away? How about getting the stock price higher so we all benefit… an unhappy long….
2 · Reply
GCPA
GCPA Apr. 2 at 5:57 PM
$MAIA This is from ANKTIVA + CPI (Keytruda or Opdivo) Phase 2 results, last september, NSCLC 2L and 3L: In total 86 pts, mOS 14.3 months In 69 (80% of 86), those with ALC >1200 after response, mOS 15.8 months. In 44 (49% of 86), those with >1500 after response, mOS 21.1 months You can more or less see in the graph that at 24 months OS should not be more than 25%, and that at 30 months it should be less than 19% (being the green curve only for 49% of patients). From recent MAIA news we only know that at least 10% (8 out of 79) of the patients have an OS >24 months.
2 · Reply
Channelchek
Channelchek Apr. 1 at 1:07 PM
Noble Capital Markets Research Report: MAIA Biotechnology ($MAIA) – MAIA Reports Two-Year Survival Data At Medical Conference New Data Presented Shows Long-Term Survival. MAIA presented data from its Phase 2 THIO-101 trial at the European Lung Cancer Congress 2026 (ELCC) held recently in Copenhagen, Denmark. The presentation included data from patients with non-small cell lung cancer (NSCLC) who had relapsed after treatment with standard chemotherapy. Read full report here: https://www.channelchek.com/news-channel/maia-biotechnology-maia-maia-reports-two-year-survival-data-at-medical-conference
0 · Reply
aku78
aku78 Mar. 31 at 11:42 PM
$MAIA great news, but it did not move the stock
2 · Reply
GCPA
GCPA Mar. 31 at 9:46 PM
$MAIA 79 patients enrolled; 8 patients with >2 years OS. What about the rest? Are they talking about these 8 because they are the only ones with >24 months of follow-up, or because they are the only ones with >24 OS?
1 · Reply
Latest News on MAIA
MAIA Biotechnology Announces $1.51 Million Private Placement

Dec 16, 2025, 4:15 PM EST - 3 months ago

MAIA Biotechnology Announces $1.51 Million Private Placement


MAIA Biotechnology Announces $736,600 Private Placement

Oct 13, 2025, 4:20 PM EDT - 6 months ago

MAIA Biotechnology Announces $736,600 Private Placement


MAIA Biotechnology Announces $2.25 Million Private Placement

Sep 29, 2025, 4:30 PM EDT - 6 months ago

MAIA Biotechnology Announces $2.25 Million Private Placement


MAIA Biotechnology to Present at BIO International Convention 2025

Jun 10, 2025, 8:46 AM EDT - 10 months ago

MAIA Biotechnology to Present at BIO International Convention 2025


MAIA Biotechnology Announces $1.08 Million Private Placement

May 5, 2025, 4:05 PM EDT - 11 months ago

MAIA Biotechnology Announces $1.08 Million Private Placement


MAIA Biotechnology Announces Private Placement of $2,715,000

Feb 18, 2025, 3:44 PM EST - 1 year ago

MAIA Biotechnology Announces Private Placement of $2,715,000


MAIA Biotechnology to Present at Biotech Showcase 2025

Jan 10, 2025, 9:45 AM EST - 1 year ago

MAIA Biotechnology to Present at Biotech Showcase 2025


focafoca99
focafoca99 Apr. 3 at 8:44 PM
$MAIA paid one-time bonuses to CEO Vlad Vitoc and finance head Jeffrey Himmelreich for work tied to the recent capital raise.
2 · Reply
LabPsycho
LabPsycho Apr. 3 at 8:18 PM
$MAIA @GISBlaster98 Have I not been posting my concerns about these guys well over a year ago? I would love to be able to hype my research, dump a ton of shares and raise 10's of millions of $$$ to at least keep a great salary coming in. How many more signs to people need this is at least a bit curious? In my opinion Cons: *Crypto gimmick * Pumper articles * Pumper video * Outrageous claims by CEO *Big pharma collaborators but not paying $$$ *Dilution, dilution and dilution more than 1 X per year * Licensed tech from somebody else * Lots of foreign collaborators * Claim of second gen Thio is a yawner IMO (i read the paper) Pros: * NIH grant (very difficult to get!) * Big pharma collaborators * Some cash for a while and still not too many shares = easy for Pump-It-Up Round 3 * My spectacular advanced ideas posted here for them for FREE of how to parlay potentially and 5X the value of their asset. * I have other ideas for them too...but why bother...nothing but crickets
2 · Reply
Chemaster
Chemaster Apr. 3 at 4:39 PM
$MAIA I'm so happy I've been here before and remain steady. Last March, I was down heavy on a stock but felt confident in the true value and didn't sell a share. Six months later the stock went up 60% and then I sold half at the top. This same situation has happened multiple times but it is difficult at times. I learned to look at value. This stock is worth $3 to $5 currently with no further data, just having strong Phase 2 data, being in Phase 3 with plenty of cash, having pan-cancer potential, specifically targeting cancer cells and leaving healthy cells untouched. The Interim Data will be here this year and if successful Big Pharma will be throwing cash at MAIA for a partnership considering the 2028 Patent Cliff. Be careful, after this long wait it's easy to sell far too soon and miss the pop. For me, I just walk my dog every morning to chill. Good Luck, steady now.
0 · Reply
Movenu
Movenu Apr. 3 at 1:28 AM
$MAIA Really wishing I sold when it hit $3 back in January but I felt so confident this would be a $10 stock soon. This company delivers as much bad news as it does good. And even the good news isn't moving the needle much lately.
2 · Reply
beforethedeluge
beforethedeluge Apr. 2 at 8:54 PM
$MAIA This thing is a year away and phase 2 doesn't mean crap. There are no guarantees. Price action looks awful. Maybe it's time to cut back a bit.
1 · Reply
GISBlaster98
GISBlaster98 Apr. 2 at 8:19 PM
$MAIA Boo! A bonus buried before a three day weekend! Geeze raise capital and give it away? How about getting the stock price higher so we all benefit… an unhappy long….
2 · Reply
GCPA
GCPA Apr. 2 at 5:57 PM
$MAIA This is from ANKTIVA + CPI (Keytruda or Opdivo) Phase 2 results, last september, NSCLC 2L and 3L: In total 86 pts, mOS 14.3 months In 69 (80% of 86), those with ALC >1200 after response, mOS 15.8 months. In 44 (49% of 86), those with >1500 after response, mOS 21.1 months You can more or less see in the graph that at 24 months OS should not be more than 25%, and that at 30 months it should be less than 19% (being the green curve only for 49% of patients). From recent MAIA news we only know that at least 10% (8 out of 79) of the patients have an OS >24 months.
2 · Reply
Channelchek
Channelchek Apr. 1 at 1:07 PM
Noble Capital Markets Research Report: MAIA Biotechnology ($MAIA) – MAIA Reports Two-Year Survival Data At Medical Conference New Data Presented Shows Long-Term Survival. MAIA presented data from its Phase 2 THIO-101 trial at the European Lung Cancer Congress 2026 (ELCC) held recently in Copenhagen, Denmark. The presentation included data from patients with non-small cell lung cancer (NSCLC) who had relapsed after treatment with standard chemotherapy. Read full report here: https://www.channelchek.com/news-channel/maia-biotechnology-maia-maia-reports-two-year-survival-data-at-medical-conference
0 · Reply
aku78
aku78 Mar. 31 at 11:42 PM
$MAIA great news, but it did not move the stock
2 · Reply
GCPA
GCPA Mar. 31 at 9:46 PM
$MAIA 79 patients enrolled; 8 patients with >2 years OS. What about the rest? Are they talking about these 8 because they are the only ones with >24 months of follow-up, or because they are the only ones with >24 OS?
1 · Reply
tradeordie24
tradeordie24 Mar. 31 at 7:17 PM
$MAIA $3+ squeeze soon?? 🍋
0 · Reply
Chemaster
Chemaster Mar. 31 at 5:08 PM
$MAIA $SLS Purchased both early today and captured the pop. Stack-up! Good luck guys!
0 · Reply
Chemaster
Chemaster Mar. 31 at 4:52 PM
$MAIA I'm loading up! Train is moving so I'm jumping in a lows that the $30B investors missed. $MAIA just dropped strong news: 8 patients in the Phase 2 THIO-101 trial for advanced NSCLC have now survived beyond 2 years with ateganosine (THIO) sequenced with cemiplimab, and no further therapies after. Highlights: • 1 third-line patient at 33 months (vs. expected ~5.8 months) • 4 second-line patients > 30 months (vs. standard-of-care median ~10.5 months) • All 8 had prior progression on a checkpoint inhibitor • Most completed 29–34 cycles; one patient stopped after just 2 cycles and is still alive at 725 days off therapy • 5 patients still in ongoing follow-up Data from ELCC 2026 poster (March 27). CEO Vlad Vitoc: “Outstanding survival… bodes well as we continue to monitor patients in our ongoing Phase 3 pivotal trial.” This is in a heavily pre-treated, immunotherapy-refractory population where options usually give single-digit months. Telomere-targeting mechanism looking more and more unique. Small n=8 subgroup out of 79 treated so far, single-arm study, but the durability (including post-treatment benefit) is impressive. Part C expansion enrolling now. Either you are in early, or you will miss the train! Just bought more to stack-um!
0 · Reply
mfritz89
mfritz89 Mar. 31 at 2:23 PM
$MAIA I feel like this news hasn't hit mainstream. I have two sources for stock news I listen to and never heard them say anything about MAIA. Only reason I got the news was a test alert through Schwab. Need some volume. Lets go!
0 · Reply
Rifraf
Rifraf Mar. 31 at 1:20 PM
0 · Reply
DekmarTrades
DekmarTrades Mar. 31 at 1:17 PM
Sean Dekmar Watch List: $NPT $MAIA $KIDZ $VRAX $ELAB
0 · Reply
DekmarTrades
DekmarTrades Mar. 31 at 1:17 PM
Watch List: $NPT $MAIA $KIDZ $VRAZ $ELAB
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 31 at 1:15 PM
$MAIA MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
0 · Reply
Find_the_Cure
Find_the_Cure Mar. 30 at 2:35 PM
$MAIA 💰💥
0 · Reply
My_Lai_1968
My_Lai_1968 Mar. 30 at 2:19 AM
$MAIA This company was nothing but clinging on to hope and a prayer. The hope is all but gone and the prayer has turned into the middle finger.
2 · Reply
lookingaroundhere
lookingaroundhere Mar. 29 at 12:36 PM
$MAIA This was a sponsored stock on Zip trader two days ago. That'll bring the discord crowd over at least 🫠
0 · Reply
Find_the_Cure
Find_the_Cure Mar. 27 at 10:54 PM
$MAIA wow. Well below the ATM public offering price. Surprising. But anything goes in this crazy market. Will re-enter on any continued weakness.
1 · Reply